OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy
of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise
hearing impairment.